ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. and Ariad Pharmaceuticals will collaborate on the development and commercialization of the Ariad cancer drug AP23573. Under the deal, Merck will pay Ariad $75 million up front and up to $452 million more in milestone payments. AP23573 is a small-molecule inhibitor of the protein mTOR, considered a "master switch" in cancer cells. The drug is expected to enter Phase III trials for the treatment of metastatic sarcomas later this quarter.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter